Literature DB >> 35960212

Commentary on Ajazi et al (2021) Re-analysis of the X:BOT Trial.

Joshua D Lee1, Edward V Nunes, Patricia Novo, Jeanine May, Abigail Matthews, Paul Van Veldhuisen, Robert Lindblad, David Liu, John Rotrosen.   

Abstract

Entities:  

Year:  2022        PMID： 35960212      PMCID： PMC9375053          DOI： 10.1097/ADM.0000000000000930

Source DB:  PubMed          Journal:  J Addict Med        ISSN： 1932-0620            Impact factor:   4.647


× No keyword cloud information.
  15 in total

1.  Overdose, suicide attempts and death among a cohort of naltrexone-treated opioid addicts.

Authors:  K Miotto; M J McCann; R A Rawson; D Frosch; W Ling
Journal:  Drug Alcohol Depend       Date:  1997-04-14       Impact factor: 4.492

2.  Comparative Effectiveness of Different Treatment Pathways for Opioid Use Disorder.

Authors:  Sarah E Wakeman; Marc R Larochelle; Omid Ameli; Christine E Chaisson; Jeffrey Thomas McPheeters; William H Crown; Francisca Azocar; Darshak M Sanghavi
Journal:  JAMA Netw Open       Date:  2020-02-05

3.  Relapse to opioid use disorder after inpatient treatment: Protective effect of injection naltrexone.

Authors:  Edward V Nunes; Michael Gordon; Peter D Friedmann; Marc J Fishman; Joshua D Lee; Donna T Chen; Mei Chen Hu; Tamara Y Boney; Donna Wilson; Charles P O'Brien
Journal:  J Subst Abuse Treat       Date:  2017-04-23

4.  Mortality among drug users after discharge from inpatient treatment: an 8-year prospective study.

Authors:  Edle Ravndal; Ellen J Amundsen
Journal:  Drug Alcohol Depend       Date:  2010-04-01       Impact factor: 4.492

5.  Effectiveness of Injectable Extended-Release Naltrexone vs Daily Buprenorphine-Naloxone for Opioid Dependence: A Randomized Clinical Noninferiority Trial.

Authors:  Lars Tanum; Kristin Klemmetsby Solli; Zill-E-Huma Latif; Jurate Šaltyte Benth; Arild Opheim; Kamni Sharma-Haase; Peter Krajci; Nikolaj Kunøe
Journal:  JAMA Psychiatry       Date:  2017-12-01       Impact factor: 21.596

6.  Fatal and non-fatal opioid overdose in opioid dependent patients treated with methadone, buprenorphine or implant naltrexone.

Authors:  Erin Kelty; Gary Hulse
Journal:  Int J Drug Policy       Date:  2017-06-10

7.  NIDA Clinical Trials Network CTN-0051, Extended-Release Naltrexone vs. Buprenorphine for Opioid Treatment (X:BOT): Study design and rationale.

Authors:  Joshua D Lee; Edward V Nunes; Patricia Novo Mpa; Genie L Bailey; Gregory S Brigham; Allan J Cohen; Marc Fishman; Walter Ling; Robert Lindblad; Dikla Shmueli-Blumberg; Don Stablein; Jeanine May; Dagmar Salazar; David Liu; John Rotrosen
Journal:  Contemp Clin Trials       Date:  2016-08-10       Impact factor: 2.226

8.  Ethical and clinical safety considerations in the design of an effectiveness trial: A comparison of buprenorphine versus naltrexone treatment for opioid dependence.

Authors:  Edward V Nunes; Joshua D Lee; Dominic Sisti; Andrea Segal; Arthur Caplan; Marc Fishman; Genie Bailey; Gregory Brigham; Patricia Novo; Sarah Farkas; John Rotrosen
Journal:  Contemp Clin Trials       Date:  2016-09-28       Impact factor: 2.226

9.  Comparative effectiveness of extended-release naltrexone versus buprenorphine-naloxone for opioid relapse prevention (X:BOT): a multicentre, open-label, randomised controlled trial.

Authors:  Joshua D Lee; Edward V Nunes; Patricia Novo; Ken Bachrach; Genie L Bailey; Snehal Bhatt; Sarah Farkas; Marc Fishman; Phoebe Gauthier; Candace C Hodgkins; Jacquie King; Robert Lindblad; David Liu; Abigail G Matthews; Jeanine May; K Michelle Peavy; Stephen Ross; Dagmar Salazar; Paul Schkolnik; Dikla Shmueli-Blumberg; Don Stablein; Geetha Subramaniam; John Rotrosen
Journal:  Lancet       Date:  2017-11-14       Impact factor: 79.321

10.  Naturalistic follow-up after a trial of medications for opioid use disorder: Medication status, opioid use, and relapse.

Authors:  Miranda G Greiner; Matisyahu Shulman; Tse-Hwei Choo; Jennifer Scodes; Martina Pavlicova; Aimee N C Campbell; Patricia Novo; Marc Fishman; Joshua D Lee; John Rotrosen; Edward V Nunes
Journal:  J Subst Abuse Treat       Date:  2021-04-30
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.